Triple-negative breast cancer (TNBC) accounts for 15–20% of incident breast cancers and is the only breast cancer (BC) subtype lacking targeted treatments. It is a biologically aggressive tumor characterized by moderate/high grade and highly proliferative cancer cells, which, together with limited treatment options, leads to the poorest prognosis among breast cancer subtypes.
BRCA gene mutations, particularly BRCA1 mutations, are strongly correlated with an increased risk of developing TNBC. As per DelveInsight’s analysis, out of all gene mutation specific TNBC cases in US in 2023, around 5,000 were BRAC gene mutation cases.
Unlike other forms of breast cancer, ...
